Glutamate is a non-invasive metabolic biomarker of IDH1 mutant glioma response to temozolomide treatment

Although lower-grade gliomas are driven by mutations in the isocitrate dehydrogenase 1 (IDH1) gene and are less aggressive than primary glioblastoma, they nonetheless generally recur. IDH1 mutant patients are increasingly being treated with temozolomide (TMZ), but early detection of response remains...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Cancer Res
Päätekijät: Subramani, Elavarasan, Radoul, Marina, Najac, Chloe, Batsios, Georgios, Molloy, Abigail R., Hong, Donghyun, Gillespie, Anne Marie, Santos, Romelyn Delos, Viswanath, Pavithra, Costello, Joseph F., Pieper, Russell O., Ronen, Sabrina M.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2020
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7669718/
https://ncbi.nlm.nih.gov/pubmed/32958546
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-20-1314
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia